Abstract: Acute kidney injury (AKI) is associated with increased morbidity and mortality and is frequently encountered in coronary care units (CCUs). Its clinical presentation differs considerably from that of prerenal or intrinsic AKI. We used the biomarkers calprotectin and neutrophil gelatinase-associated lipocalin (NGAL) and compared their utility in predicting and differentiating intrinsic AKI.

This was a prospective observational study conducted in a CCU of a tertiary care university hospital. Patients who exhibited any comorbidity and a kidney stressor were enrolled. Urinary samples of the enrolled patients collected between September 2012 and August 2013 were tested for calprotectin and NGAL. The definition of AKI was based on Kidney Disease Improving Global Outcomes classification. All prospective demographic, clinical, and laboratory data were evaluated as predictors of AKI.

A total of 147 adult patients with a mean age of 67 years were investigated. AKI was diagnosed in 71 (50.3%) patients, whereas intrinsic AKI was diagnosed in 43 (60.5%) of them. Multivariate logistic regression analysis revealed urinary calprotectin and serum albumin as independent risk factors for intrinsic AKI. For predicting intrinsic AKI, both urinary NGAL and calprotectin displayed excellent areas under the receiver operating characteristic curve (AUROC) of 0.918 and 0.946, respectively. A combination of these markers revealed an AUROC of 0.946. Our result revealed that calprotectin and NGAL had considerable discriminative powers for predicting intrinsic AKI in CCU patients. Accordingly, careful inspection for medication, choice of therapy, and early intervention in patients exhibiting increased biomarker levels might improve the outcomes of kidney injury.

(Medicine 94(40):e1703)

INTRODUCTION

Acute kidney injury (AKI) is a common complication responsible for increased medical expenditure and poor outcome in hospital settings.1–2 Its incidence varies from 28% to 75% based on etiologies and has increased in the past decade.3–7 In addition, AKI developing after admission to a coronary care unit (CCU) is not only associated with 10-fold increased mortality but also long-term complications.8–9 Even minor alterations in serum creatinine (SCr) levels (>0.25 mg/dL) following angiography are associated with increased mortality.10 In 2007, the Acute Kidney Injury Network (AKIN) group proposed modified standard criteria called RIFLE: Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal failure. Based on the RIFLE criteria, the AKIN group enrolled patients who exhibited an increase in SCr levels to 0.3 mg/dL within 48 hours. Although this change increased the sensitivity of AKI detection, several studies have assessed and suggested that these criteria enrolled patients with prerenal AKI11,12 Patients admitted to CCUs typically exhibit complex syndromes with numerous pathways that affect renal function. Especially, AKI typically develops following acute myocardial infarction (AMI), congestive heart failure (CHF), arrhythmia, sepsis, and contrast medium injection, which also cause prerenal AKI. In addition, medical interventions such as fluid restriction and administration of diuretics, angiotensin-converting enzyme inhibitors, and aldosterone receptor blockers increase the risk of prerenal azotemia and kidney injury. By definition, renal dysfunction that recovers within 72 hours after injury is termed prerenal AKI.13,14 Reportedly, prerenal azotemia occurs in 32.1% of AKI cases in hospital settings and is associated with increased mortality.15 Two other studies have revealed that patients in whom AKI persists for >3 days exhibit higher long-term mortality than do those in whom AKI resolved within 3 days.14,15 Despite the lack of any previous investigations, we believe that the prevalence of prerenal AKI is much higher in CCU settings as a result of cardiac dysfunction and diuretics usage. In contrast, intrinsic AKI is caused by prolonged or severe kidney injury.16 At the cellular biology level, an intrinsic injury leads to apoptosis or necrosis of the renal tubule cells that...
fail to adapt to the stress. Traditionally, fractional excretion of sodium (FE\text{Na}) and urea (FE\text{Urea}) are commonly used parameters to discriminate prerenal from intrinsic AKI. However, certain drawbacks have been disclosed in previous studies. For example, FE\text{Na} is unreliable in patients who are older or those with heart failure or diuretic use. FE\text{Urea} is affected by protein and fluid intake, and it also lacks specificity.\textsuperscript{17–19} Currently, novel biomarkers are developed to identify patients with renal tubular injury, which could be helpful for early prediction of the clinical course of the disease and help doctors in making appropriate clinical decisions.\textsuperscript{20,21} However, a study reported mildly increased neutrophil gelatinase-associated lipocalin (NGAL) in patients who developed prerenal AKI after cardiogenic shock.\textsuperscript{22} Moreover, studies have reported calprotectin as a favorable differential marker for prerenal AKI.\textsuperscript{23,24} Thus, the purpose of this research was to examine whether NGAL and calprotectin can distinguish intrinsic from prerenal disease without dedicating whole paragraphs on AKI but focus on cardio-renal syndrome. To the best of our knowledge, this is the first investigation that combined risk-evaluation strategy and biomarkers to discriminate intrinsic AKI in a CCU setting. The findings of this study may guide practitioners in identifying and treating patients at risk of AKI.

MATERIALS AND METHODS

Study Design, Patient Information, and Data Collection

This cross-sectional study was performed in the CCU at a tertiary care referral center in Taiwan between September 2012 and August 2013. The study protocol was approved by the local Institutional Review Board. Patients who exhibited any of the comorbidities of AKI and any of the kidney stressors were enrolled in this investigation. The following comorbidities were considered as risk factors for AKI: age \textgreater 65 years, diabetes mellitus, CHF (functional class III or IV), and chronic kidney disease (CKD, defined as estimated glomerular filtration rate \textless 60 mL/min).\textsuperscript{25} In addition, the following conditions when observed during the period from before admission were considered as kidney stressors: AMI (defined according to the 2007 Expert Consensus Document of Circulation, European Heart Journal), shock (systolic pressure \textless 90 mm Hg, or use of any inotropic agent to maintain blood pressure or cardiac output), arrhythmia (ventricular fibrillation, ventricular flutter, or third-degree atrioventricular block), sepsis (defined according to the American College of Chest Physicians/Society of Critical Care Medicine [ACCP/SCCM Consensus Conference], renal toxin exposure (contrast medium, nonsteroidal anti-inflammatory drug, and aminoglycoside), and mechanical ventilator support. Patients who were receiving dialysis, ages <18 years, or reported prior organ transplantation were excluded. To ensure early detection, only those patients who were admitted to CCU within 72 hours from the emergency department were enrolled. Because calprotectin was considered as a confounding factor, patients with urinary tract infections or gross hematuria after indwelling urinary catheter were excluded based on a previous study.\textsuperscript{24} According the study, the median level of calprotectin for the healthy control and intrinsic AKI was 45 ng/mL (19–139 ng/mL) and 1692 ng/mL (765–4735 ng/mL), respectively.\textsuperscript{26} Given the type I error of 0.05 and power of 0.90, resulting a minimum sample size of 72 urinary calprotectin data to detect an intrinsic AKI. The determination of sample size was performed using nonparametric Mann–Whitney U test procedure of NCSS 2007 (Number Cruncher Statistical System, Limited Liability Company, Kaysville, Utah).

To determine the predictive value of biomarkers for intrinsic AKI, the primary outcome was the development of AKI within 7 days after admission. Based on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Acute Kidney Injury, AKI was confirmed under any of the following conditions: SCr levels \textgreater 0.3 mg/dL within 48 hours or \textgreater 1.5 times increase in SCr levels from baseline within 7 days.\textsuperscript{26,27} In addition, the severity of AKI was staged according to the KDIGO guideline. Definitions of prerenal AKI and intrinsic AKI were modified based on a prior study conducted by the Westhoff group (Table 1).\textsuperscript{28} To assess the prognostic utility of biomarkers, 6-month mortality was considered as the secondary outcome. After hospital discharge, 6-month follow-up examinations were performed by reviewing the follow-up records or using telephone interviews as needed.

The following data were collected prospectively: demographic characteristics, primary diagnosis, routine biochemistry tests, and treatment outcomes. Overall, 151 patients provided informed consent, but 4 of these were excluded from analysis because repeated kidney injuries were observed after sample collection. A total of 147 patients were enrolled in this study.

Sampling and Quantifying Urinary Neutrophil Gelatinase-Associated Lipocalin and Calprotectin

Urinary samples were collected in sterile nonheparinized tubes immediately after admission and then centrifuged at

### TABLE 1. Diagnostic Criteria for Prerenal AKI and Intrinsic AKI in CCUs

| Clinical Criteria | Prerenal AKI | Intrinsic AKI |
|-------------------|-------------|---------------|
| Category A clinical history | Rapid decrease of Cr with convergence to baseline within 72 hours | No reconstitution of renal function or slow recovery of renal function >72 hours |
| Category B history | Heart failure, arrhythmia | NSAID, aminoglycoside, contrast exposure |
| Physical findings compatible | Low jugular pulse, high CVP level, poor skin turgor, pulmonary edema | Absence of signs of dehydration |
| Urine examinations | Absence of proteinuria, hematuria, and leukocyturia | Proteinuria and/or hematuria and/or leukocyturia |

Definition of AKI: Cr increases \textgeq 1.5 \times \text{from baseline within 7 d or Cr increases} \textgeq 0.3 mg within 48 h. The criteria of category A are obligatory and criteria of category B are optional for the diagnosis of prerenal or intrarenal AKI. Diagnosis of prerenal AKI required 2 criteria of category B and the obligatory criterion of category A. AKI = acute kidney injury, CCU = coronary care unit, Cr = creatinine, CVP = central venous pressure, NSAID = nonsteroidal anti-inflammatory drugs.
clarified supernatants were stored at –80 °C for 6 months before measurement. Urinary neutrophil NGAL and calprotectin levels were measured in duplicate by using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer’s instructions (R&D Systems, DCLN20, McKinley Place NE Minneapolis; MPLS, USA and Phi Cal® Calprotectin, K 6935; and Immunodiagnostik AG, Bensheim, Germany). The intra-assay coefficients of variability for urine NGAL and urine calprotectin were 9.06% and 11.28%, respectively (n = 4).

**Statistical Analysis**

Continuous variables were shown as the mean and standard error (SE). The Kolmogorov–Smirnov test was used to determine the normal distribution of each variable. The continuous variables of the non-AKI, prerenal AKI, and intrinsic AKI groups were analyzed using repeated-measures analysis of variance (ANOVA) by the Tukey’s honestly significant difference test for post hoc analysis. The categorical data were analyzed using χ² test. The predictive parameters for intrinsic AKI were assessed using univariate analysis, and the statistically significant variables were included in multivariate analysis by using a multiple logistic regression model based on backward elimination of data.

The Hosmer–Lemeshow goodness-of-fit test was used for calibration when evaluating the number of observed and predicted intrinsic AKI cases in the risk groups for the entire range of probabilities. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC). The AUROC analysis calculated cut-off values, sensitivity, specificity, and overall accuracy. Subsequently, cut-off points were calculated by acquiring the optimal Youden index. The Youden index has minimum and maximum values of −1 and +1, respectively, and a value of +1 is considered the optimal value for an algorithm. Cumulative survival curves were assessed using the Kaplan–Meier approach. To determine the combined discriminative ability of biomarkers, the multiple logistic regression model was applied with both NGAL and calprotectin as independent variables. P value of <0.05 was considered statistically significant.

**TABLE 2.** Demographic Data and Clinical Characteristics on Admission of Non-AKI, Prerenal AKI, and Intrinsic AKI Group Patients

| Demographic data | All Patients (n = 147) Non-AKI (n = 73) Prerenal AKI (n = 31) Intrinsic AKI (n = 43) |
|------------------|---------------------------------|---------------------------------|---------------------------------|
| Age, yr          | 67 ± 1                          | 63 ± 1                          | 68 ± 2                          | 71 ± 2*                          |
| Gender, male (%) | 100 (68)                        | 54 (74)                         | 19 (61)                         | 27 (63)                          |
| Hypertension (%) | 101 (69)                        | 47 (64)                         | 22 (71)                         | 32 (74)                          |
| History of CAD (%) | 101 (69)                     | 57 (78)                         | 22 (71)                         | 22 (51)                          |
| Clinical parameter |                                 |                                 |                                 |                                 |
| Mean arterial pressure, mm Hg | 90 ± 6                      | 83 ± 2                          | 118 ± 32                        | 84 ± 4                           |
| Glasgow coma scale, points | 14 ± 0                      | 15 ± 0                          | 14 ± 1*                         | 12 ± 1*                          |
| AST, U/L         | 51 ± 7                          | 40 ± 5                          | 54 ± 13                         | 71 ± 20                          |
| Blood sugar, mg/dL | 162 ± 7                      | 155 ± 9                         | 181 ± 25                        | 163 ± 11                         |
| Serum creatinine baseline | 1.8 ± 0.2                    | 1.7 ± 0.3                       | 1.7 ± 0.2                       | 1.9 ± 0.3                        |
| Serum creatinine at CCU, mg/dL | 2.2 ± 0.2                    | 1.7 ± 0.3                       | 2.6 ± 0.3                       | 3.1 ± 0.3                        |
| Total bilirubin, mg/dL | 0.7 ± 0.0                     | 0.7 ± 0.0                       | 0.9 ± 0.2                       | 0.6 ± 0.1                        |
| Albumin, g/L     | 3.6 ± 0.0                       | 3.8 ± 0.0                       | 3.5 ± 0.1*                      | 3.2 ± 0.1*                       |
| Hemoglobin, g/dL | 12.3 ± 0.3                      | 13.4 ± 0.3                      | 12.1 ± 0.6*                     | 11.1 ± 0.3*,**                   |
| Leukocytes, ×10⁹/µL | 10.6 ± 0.6                     | 9.6 ± 0.4                       | 10.5 ± 0.6                      | 12.6 ± 1.9*                      |
| Serum sodium, mmol/L | 138 ± 0                      | 139 ± 0                         | 140 ± 1                         | 138 ± 1*                         |
| CRP, mg/L        | 46 ± 6                          | 27 ± 5                          | 53 ± 16                         | 97 ± 17                          |
| Troponin I, ng/mL | 6.6 ± 1.4                       | 5.4 ± 1.5                       | 9.9 ± 4.7                       | 6.6 ± 2.6                        |
| BNP, pg/mL       | 977 ± 108                       | 509 ± 89                        | 1055 ± 213                      | 1753 ± 257*                     |
| Ejection fraction, % | 52 ± 2                       | 54 ± 2                          | 49 ± 4                          | 50 ± 4                           |
| Biomarkers       |                                 |                                 |                                 |                                 |
| Urine NGAL, ng/mL | 135.2 ± 26.5                   | 56.1 ± 28.5                     | 49.4 ± 14.4                     | 329.3 ± 63.6*,**,**             |
| Urine calprotectin, ng/mL | 886.1 ± 166.4               | 195.8 ± 89.0                    | 385.2 ± 271.7                   | 2404.5 ± 417.9*,**,**           |
| Urine NGAL, ng/mL/urine Cr, mg/dL | 2.6 ± 8.0                   | 1.7 ± 9.0                       | 0.6 ± 1.1                       | 6.4 ± 8.4*,**                  |
| Urine calprotectin, ng/mL/urine Cr, mg/dL | 13.7 ± 36.1                | 1.8 ± 4.5                       | 3.1 ± 9.8                       | 47.1 ± 59.5*,**,**            |
| Outcomes (or prognosis) |                                 |                                 |                                 |                                 |
| Renal replacement therapy within 7 d | 9 (6.1)                     | 0                               | 0                               | 9 (20.9)**                       |
| In-hospital death | 11 (7.5)                        | 2 (2.7)                         | 1 (3.2)                         | 8 (18.6)**                       |
| 6 mo mortality   | 14 (9.5)                        | 3 (4.1)                         | 3 (9.7)                         | 8 (18.6)**                       |

AKI = acute kidney injury, AST = aspartate aminotransferase, BNP = B-type natriuretic peptide, CAD = coronary arterial disease, CCU = coronary care unit, CRP = C reactive protein, NGAL = neutrophil gelatinase-associated lipocalin.

* P < 0.05 compared with non-AKI.
** P < 0.05 compared with prerenal-AKI.
*** P < 0.05 by Pearson’s chi-square for trend for categorical data.
RESULTS

Study Population Characteristics

Overall, 147 adult patients (100 men and 47 women), with a mean age of 67 years were investigated. AKI was diagnosed in 71 (50.3%) patients, of which, 43 (60.5%) were diagnosed with intrinsic AKI. The patient characteristics included age, sex, hematological parameters, and biomarker levels, as listed in Table 2. Hypertension and coronary arterial disease were recorded in 69% of patients during recruitment. The mean urinary NGAL levels were 56.1 ± 28.5, 49.4 ± 14.4, and 329.3 ± 63.6 ng/mL in the non-AKI, prerenal, and intrinsic AKI groups, respectively (P < 0.001); moreover, the mean urinary calprotectin levels were 195.8 ± 89.0, 385.2 ± 271.7, and 2404.5 ± 417.9 ng/mL, respectively (P < 0.001) (Figure 1). The mean urinary NGAL levels were 56.1 ± 28.5, 49.4 ± 14.4, and 329.3 ± 63.6 ng/mL in the non-AKI, prerenal, and intrinsic AKI groups, respectively (P < 0.001); moreover, the mean urinary calprotectin levels were 195.8 ± 89.0, 385.2 ± 271.7, and 2404.5 ± 417.9 ng/mL, respectively (P < 0.001). For large variability observed within the 3 groups, the NGAL and calprotectin was adjusted to urine Cr. The mean urinary NGAL/Cr levels were 56.1 ± 28.5, 49.4 ± 14.4, and 329.3 ± 63.6 ng/mL in the non-AKI, prerenal, and intrinsic AKI groups, respectively (P < 0.001); and, the mean urinary calprotectin/Cr levels were 195.8 ± 89.0, 385.2 ± 271.7, and 2404.5 ± 417.9 ng/mL, respectively (P < 0.001). Nine intrinsic AKI group patients had received hemodialysis. Overall, 14 (9.5%) patients died before the 6-month follow-up. Table 2 summarizes the patient characteristics according to the different AKI categories. The intrinsic AKI group patients were significantly older and exhibited significantly higher SCr levels, WBC counts, and B-type natriuretic peptide (BNP), NGAL, and calprotectin levels than did the non-AKI group patients. In addition, the intrinsic AKI group patients exhibited lower coma scale scores and albumin, hemoglobin, and serum sodium levels than did the non-AKI group patients. However, the prerenal and intrinsic AKI groups revealed significant differences in only the hemoglobin, NGAL, and calprotectin levels. Table 3 lists the characteristics evaluated for risk-factor analysis among all groups. The intrinsic AKI group patients exhibited significantly higher incidence of severe heart failure, CKD, and sepsis. The ratio

![FIGURE 1. Individual measurement results of urinary NGAL and calprotectin levels of intrinsic acute kidney injury (AKI), prerenal AKI, and non-AKI of the complete study population. The data are presented as scatter plots (logarithmic scale; medians are indicated by horizontal lines). Both concentrations of NGAL and calprotectin in intrinsic AKI were significantly higher than prerenal and non-AKI. NGAL = neutrophil gelatinase-associated lipocalin.](#)
of AMI and renal toxin exposure was significantly lower in the intrinsic AKI group. In addition, significant differences were observed in the cumulative survival rates \( (P < 0.05) \) between the non-AKI and the prerenal and intrinsic AKI groups at the 6-month follow-up (Appendix 2, http://links.lww.com/MD/A447). Unfavorable outcome was also noted in the patients whose NGAL exceeded 39.0 ng/mL or calprotectin exceeded 314.6 ng/mL, respectively (Appendices 3 and 4, http://links.lww.com/MD/A447).

**Urinary NGAL and Calprotectin in Intrinsic AKI**

Although age, coma scale scores, severe CHF, AMI, and SCR, albumin, hemoglobin, BNP, CKD, urinary NGAL, and calprotectin levels were associated with AKI according to the univariate analysis, only SCR, hemoglobin, and calprotectin levels were independently associated with intrinsic AKI according to the multivariate analysis (Table 4). For a 1-U (1 pg/mL) increase in the calprotectin levels, an approximately 0.1% increase was expected in the risk of that particular event of AMI and renal toxin exposure was significantly lower in the intrinsic AKI group. In addition, significant differences were observed in the cumulative survival rates \( (P < 0.05) \) between the non-AKI and the prerenal and intrinsic AKI groups at the 6-month follow-up (Appendix 2, http://links.lww.com/MD/A447). Unfavorable outcome was also noted in the patients whose NGAL exceeded 39.0 ng/mL or calprotectin exceeded 314.6 ng/mL, respectively (Appendices 3 and 4, http://links.lww.com/MD/A447).

### TABLE 3. Risk Factor Analysis for Intrinsic AKI

| Comorbidity            | All Patients (n = 147) | Non-AKI (n = 73) | Prerenal AKI (n = 31) | Intrinsic AKI (n = 43) |
|------------------------|------------------------|------------------|----------------------|-----------------------|
| Age ≥ 65               | 84 (57)                | 36 (49)          | 21 (68)              | 27 (63)               |
| Diabetes mellitus, n (%) | 63 (43)                | 29 (40)          | 10 (32)              | 24 (56)               |
| CHF III or IV, n (%)   | 60 (41)                | 17 (23)          | 17 (55)              | 23 (54)               |
| CKD, n (%)             | 47 (32)                | 11 (15)          | 9 (29)               | 27 (63)               |
| Number of comorbidity  | 1.3 ± 0.9              | 1.8 ± 1.1        | 2.3 ± 1.0            | 1.7 ± 1.1             |
| Kidney stressor        |                        |                  |                      |                       |
| AMI, n (%)             | 81 (55)                | 55 (75)          | 16 (52)              | 21 (48)               |
| Shock, n (%)           | 26 (18)                | 10 (14)          | 8 (26)               | 8 (19)                |
| Arrhythmia, n (%)      | 21 (14)                | 6 (8)            | 3 (10)               | 6 (14)                |
| Sepsis, n (%)          | 17 (12)                | 5 (7)            | 5 (12)               | 7 (16)                |
| Renal toxin exposure, n (%) | 72 (49)            | 47 (64)          | 14 (45)              | 11 (26)               |
| Mechanical ventilation, n (%) | 20 (14)             | 5 (7)            | 6 (20)               | 9 (21)                |
| Number of kidney stressor | 1.8 ± 0.8             | 1.6 ± 1.2        | 1.4 ± 1.0            | 1.6 ± 1.0             |

Arrhythmia (ventricular fibrillation, ventricular flutter or third-degree atrioventricular block). Renal toxin exposure included contrast, NSAID, aminoglycoside. Number of comorbidity and kidney stressor was expressed as mean ± SD. AKI = acute kidney injury, AMI = acute myocardial infarction, CHF = congestive heart failure, CKD = chronic kidney disease, NGAL = neutrophil gelatinase-associated lipocalin, SD = standard deviation.

\( P < 0.05 \) by Pearson’s chi-square for trend for categorical data.

### TABLE 4. Logistic Regression Analysis for Intrinsic AKI Based on Baseline Prognostic Factors on CCU Admission

| Parameter                                      | Beta Coefficient | Standard Error | Odds Ratio (95% CI) | \( P \)  |
|------------------------------------------------|------------------|----------------|---------------------|---------|
| **Univariate logistic regression**             |                  |                |                     |         |
| Age                                            | 0.031            | 0.016          | 1.032 (1.000–1.064) | 0.047   |
| Glasgow coma scale                             | −0.185           | 0.059          | 0.831 (0.740–0.934) | 0.002   |
| Serum creatinine, at CCU                       | 0.279            | 0.096          | 1.321 (1.095–1.594) | 0.004   |
| Albumin                                        | −1.821           | 0.435          | 0.162 (0.060–0.309) | <0.001  |
| Hemoglobin                                     | −0.538           | 0.109          | 0.484 (0.371–0.623) | 0.006   |
| Leukocytes (×10³/μL)                           | 0.000            | 0.000          | 1.000 (1.000–1.000) | NS (0.558)|
| Serum sodium (mmol/L)                          | −0.027           | 0.045          | 0.973 (0.891–1.063) | NS (0.544)|
| BNP                                            | 0.001            | 0.000          | 1.001 (1.000–1.001) | <0.001  |
| CHF III or IV                                  | 0.862            | 0.370          | 2.368 (1.146–4.893) | 0.020   |
| CKD                                            | 1.958            | 0.402          | 7.087 (3.225–15.578)| <0.001  |
| MI                                             | −0.813           | 0.371          | 0.444 (0.215–0.918) | 0.028   |
| Sepsis                                         | 0.819            | 0.537          | 2.269 (0.793–6.496) | NS (0.127)|
| Urine NGAL                                     | 0.005            | 0.001          | 1.005 (1.003–1.008) | <0.001  |
| Urine calprotectin                             | 0.001            | 0.000          | 1.001 (1.000–1.001) | <0.001  |
| **Multivariate logistic regression**           |                  |                |                     |         |
| Serum creatinine, at CCU                       | 0.295            | 0.170          | 1.343 (0.962–1.875) | NS (0.084)|
| Hemoglobin                                     | −0.461           | 0.146          | 0.630 (0.473–0.840) | 0.002   |
| Urine calprotectin                             | 0.001            | 0.000          | 1.001 (1.000–1.001) | 0.001   |
| Constant                                       | 2.882            | 1.730          | –                   | –       |

AKI = acute kidney injury, AMI = acute myocardial infarction, BNP = B-type natriuretic peptide, CCU = coronary care unit, CHF = congestive heart failure, CI = confidence intervals, CKD = chronic kidney disease, NGAL = neutrophil gelatinase-associated lipocalin, NS = not significant.
(95% confidence interval [CI] = 1.000–1.001, \( P < 0.001 \)). The levels of both biomarkers were compared according to AKI staging. No significant differences were observed in the NGAL levels across the various aforementioned categories. Concurrently, the urinary calprotectin levels at stage 3 AKI were significantly higher than those at the other stages (Figure 2).

**DISCUSSION**

Patients admitted to CCUs typically exhibit complex syndromes with numerous pathways that affect renal function. Decision making for patients with AKI is challenging, particularly when the treatments administered to patients with prerenal AKI and those with intrinsic AKI are markedly different. We conducted a biomarker study integrated with a risk-evaluation strategy. Compared with the findings of our previous study, the incidence of AKI increased twofold, from 28.7% to 50.3%, respectively. Compared with calprotectin alone, a combination of both markers did not improve the diagnostic accuracy (AUROC = 0.946), indicating there was no incremental value of NGAL in diagnosing intrinsic AKI when calprotectin was considered.

**Discrimination Power of Urinary NGAL and Calprotectin in Predicting Intrinsic AKI**

The accuracy of the urinary biomarkers NGAL and calprotectin in the detection of intrinsic AKI was assessed through ROC curve analysis (Table 5). The ROC analysis of NGAL and calprotectin revealed AUROCs of 0.918 and 0.946, respectively. The Youden index was used to determine the optimal cut-off value to differentiate prerenal and intrinsic AKI. As shown in Appendix 1, http://links.lww.com/MD/A447, NGAL exhibited a sensitivity of 93.0% and a specificity of 83.0% for a threshold value of 39.0 ng/mL, whereas urinary calprotectin exhibited a sensitivity of 88.4% and a specificity of 96% for a cut-off value of 314.6 ng/mL. The overall accuracy of NGAL and calprotectin was 83.7% and 91.2%, respectively. Compared with calprotectin alone, a combination of both markers did not improve the diagnostic accuracy (AUROC = 0.946), indicating there was no incremental value of NGAL in diagnosing intrinsic AKI when calprotectin was considered.

**NGAL**

NGAL, also known as lipocalin-2 (LCN2), is a 25-kDa protein encoded by the LCN gene, which was originally identified in neutrophils as a shuttle for iron transport to inhibit bacterial growth.\(^{35} \) In addition, NGAL expression has been identified in the kidney and liver in response to inflammation, infection, intoxication, ischemia, neoplastic formation, and AKI.\(^{39–42} \) NGAL also has antiapoptotic effects and an ability to induce tubular cell proliferation, and these constitute the possible pathways of NGAL-mediated kidney protection in AKI. In a healthy population, minute levels of NGAL are filtered from inside the glomerulus and the luminal NGAL is reabsorbed in the proximal tubule through a megalin-dependent pathway.\(^{45} \) Immediately after AKI, NGAL is upregulated in the ascending limb of the Henle’s loop, the distal tubule, and the collecting duct. Moreover, impaired proximal reabsorption during the onset of proximal tubular absorption upregulates urinary NGAL levels.\(^{43} \) Numerous studies have reported the potential clinical utility of NGAL in AKI. In our previous study, urinary NGAL revealed an AUROC of 0.796 with a cut-off value of 33 ng/mL.\(^{8} \) This finding provides further evidence that NGAL may be effective in treating AKI.

**Calprotectin**

Calprotectin (S100A8/S100A9) is a 36-kDa heterodimer of 2 calcium-binding proteins identified in the cytoplasm of neutrophils and monocytes that was initially discovered as an antimicrobial protein.\(^{44} \) Calprotectin is released in the circulation or body fluids on neutrophil activation or endothelial adhesion. In addition, it is implicated in the recruitment of inflammatory cells to amplify the inflammatory cascade through innate immunity with Toll-like receptor (TLR) 4 as the damage-associated molecular pattern protein.\(^{45–46} \) Several studies have demonstrated its role in inflammatory bowel

![Figure 2](http://links.lww.com/MD/A447) Different expression levels of urinary NGAL and calprotectin according to differ severity of AKI. Only concentrations of calprotectin in stage 3 AKI show the differences compared with AKI stage 1 and stage 2. AKI = acute kidney injury, NGAL = neutrophil gelatinase-associated lipocalin.
Innate immunity is activated through TL2 and TL4 present in the tubular cells that are involved in the cellular mechanism of AKI. Caspase-1 mediates inflammation via the activation of interleukin-1β and interleukin-18 (IL-18). Caspase-3 is a major mediator of both apoptotic and necrotic cell death and also involves in calprotectin-mediated apoptosis. Increases in both caspase-1 and caspase-3 have been described in ischemic injury to various organs including brain, heart, and kidney. These evidences support the role of inflammation on cardiorenal interaction.

In the present study, urinary calprotectin may have been released from the infiltrating leukocytes because of tubular damage or circulation. In a study on 101 patients with AKI admitted in a nephrology ward, Westhoff et al demonstrated that urinary calprotectin exhibited an AUROC of 0.97 with a cut-off value of 300 ng/mL, wherein various diseases, such as hepatorenal syndrome, cardiorenal syndrome, and renal artery stenosis, were evaluated. In this study, patients with urinary tract infections also exhibited significantly increased calprotectin levels. They also conducted a second investigation on 87 patients (38 with AKI, 24 with prerenal AKI, and 25 healthy controls) and reported that urinary calprotectin exhibited an AUROC of 0.99, where as NGAL exhibited an AUROC of 0.82 with cut-off values of 440 and 52 ng/mL, respectively. Another research by Han et al reported that a combination of biomarkers might improve the accuracy of diagnosing AKI after cardiac surgery. In our study, the discriminatory powers of calprotectin, urinary NGAL, or a combination of these markers were similar (0.918 vs 0.946 vs 0.946, respectively). There were 2 possible explanations. First, urinary NGAL is immediately released after open heart surgery, whereas persistent elevation of NGAL suggests ongoing kidney damage, which implicates the inflammatory cascade and releases calprotectin. Second, our risk-evaluation strategy might have excluded patients who exhibited confounding factors that interfere biomarkers. Thus, single biomarker to detect intrinsic AKI was recommended. This might also explain that calprotectin, rather than NGAL, was the only biomarker retained in the multivariate analysis for intrinsic AKI.

Currently, AKI definition was based on Cr change, this might decrease the diagnosis of AKI, since some patients already had AKI at the time of admission. On the other hand, these patients could have higher levels of biomarkers, interfering with their performance to predict AKI and its associated prognosis. We acknowledge Chen et al for this work. Thus, NGAL and calprotectin have its clinical application for intrinsic AKI. Furthermore, to insure the influence of urine concentration on biomarkers, the levels of NGAL and calprotectin were adjusted to urine Cr (Figure 1). In view of baseline differences and dynamic change of Cr excretion during AKI, it may be useful to compare the normalized biomarker levels to baseline, in order to account for inter-individual differences in baseline Cr excretion rates. This area deserves further investigation. The possible explanation large variability within group is that the level of these markers might reflect the severity of disease and also predict the prognosis. The appendices 3 and 4, http://links.lww.com/MD/A447 illustrated the higher mortality rate in patients with NGAL exceeding 39.0 ng/mL or calprotectin exceeding 314.6 ng/mL.

This study has several limitations. First, only 1 measurement of the NGAL and calprotectin levels was used in this cross-sectional study to predict the incidence of intrinsic AKI. Repeat measurements to detect secondary kidney damage may improve the predictive ability. Second, the roles and expression of calprotectin in chronic active glomerulus nephritis require further investigation. Third, we excluded urinary tract infections and gross hematuria related to catheter trauma that influences the urinary NGAL and calprotectin levels. Therefore, meticulous clinical inspection and interpretation methods must be implemented for asymptomatic pyuria. Fourth, this study considered AKI identified in a 7-day period alone; thus, studies with long-term follow-up periods are warranted to explore the relationship between mortality and the concerned biomarkers. Fifth, this research was conducted on a heterogeneous population, and no subgroup analysis was conducted to explore the relationships between a specific disease type and the biomarkers. Finally, considering the small sample size and observational design, additional prospective randomized trials are warranted for verifying the cost efficacy of using these markers to modify clinical pathways. The assessments of NGAL and calprotectin levels were expensive and time consuming. There are few data on the influence of prolonged duration of storage at −80°C on the stability of urinary markers at the present time. Before clinical application, prospective studies including healthy individuals should be performed to standardize the protocols and facilitate the creation of reproducible assays.

In summary, we present 2 inferences of this investigation. First, an appropriate risk-evaluation strategy could improve the
detection rate of AKI and reduce the cost of biomarker assessments in clinical practice. Second, increased urinary NGAL and calprotectin levels are both accurate in distinguishing intrinsic AKI from prerenal azotemia in a CCU setting. The novelty of present study could be a reliable noninvasive test in clinical implication to differentiate intrinsic from prerenal AKI and it would shorten the time to initiation of appropriate therapy. Increased urinary calprotectin levels serve as independent and accurate predictors of intrinsic AKI. The results indicate the crucial role of inflammation as an unfavorable factor in persistent kidney damage. Accordingly, careful inspection for medication, choice of therapy, and early intervention in patients exhibiting increased biomarker levels might improve the outcomes of kidney injury.

ACKNOWLEDGMENT
The authors thank Yi-Ching Ko, Yi-Fan Gan, Ya-Ting Zhuang, and Shu-Yun Wang for their assistance in analysis, sampling, and data collection.

REFERENCES
1. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365–3370.
2. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int. 1996;50:811–818.
3. Wong CS, Lee WC, Jenq CC, et al. Scoring short-term mortality after liver transplantation. Liver Transplant. 2010;16:138–146.
4. Chen YC, Tsai FC, Chang CH, et al. Prognosis of patients on extracorporeal membrane oxygenation: the impact of acute kidney injury on mortality. Ann Thorac Surg. 2011;91:137–142.
5. Lin CY, Kao KC, Tian YC, et al. Outcome scoring systems for acute respiratory distress syndrome. Shock. 2010;34:352–357.
6. Jenq CC, Tsai MH, Tian YC, et al. RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. Intens Care Med. 2007;33:1921–1930.
7. Waakar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol. 2006;17:1143–1150.
8. Chen TH, Chang CH, Lin CY, et al. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. PLoS ONE. 2012;7:e32328.
9. Parikh CR, Coca SG, Wang Y, et al. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med. 2008;168:987–995.
10. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17:2871–2877.
11. Engleberger L, Suri RM, Li Z, et al. Clinical accuracy of RIFLE and Acute Kidney Injury Network (AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care. 2011;15:R16.
12. Chang CH, Lin CY, Tian YC, et al. Acute kidney injury classification: comparison of AKIN and RIFLE criteria. Shock. 2010;33:247–252.
13. Uchino S, Bellomo R, Bagshaw SM, et al. Transient azotemia is associated with a high risk of death in hospitalized patients. Nephrol Dial Transplant. 2010;25:1833–1839.
14. Coca SG, King JT Jr, Rosenthal RA, et al. The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans. Kidney Int. 2010;78:926–933.
15. Brown JR, Kramer RS, Coca SG, et al. Duration of acute kidney injury impacts long-term survival after cardiac surgery. Ann Thorac Surg. 2010;90:1142–1148.
16. Pons B, Lautrette A, Oziel J, et al. Diagnostic accuracy of early urinary index changes in differentiating transient from persistent acute kidney injury in critically ill patients: multicenter cohort study. Crit Care. 2013;17:R56.
17. Steiner RW. Interpreting the fractional excretion of sodium. Am J Med. 1984;77:699–702.
18. Pepin MN, Bouchard J, Legault L, et al. Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. Am J Kidney Dis. 2007;50:566–573.
19. Darmon M, Vincent F, Dellamonica J, et al. Diagnostic performance of fractional excretion of urea in the evaluation of critically ill patients with acute kidney injury: a multicenter cohort study. Crit Care. 2011;15:178.
20. Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol. 2011;22:816–820.
21. Coca SG, Yalavarthy R, Concato J, et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008–1016.
22. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22:1748–1757.
23. Seibert FS, Pagonas N, Arndt R, et al. Calprotectin and neutrophil gelatinase-associated lipocalin in the differentiation of pre-renal and intrinsic acute kidney injury. Acta Physiol (Oxf, Engl). 2013;207:700–708.
24. Heller F, Frischmann S, Gruenbaum M, et al. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol. 2011;6:2347–2355.
25. Goldstein SL, Chawla LS. Renal angina. Clin J Am Soc Nephrol. 2010;5:943–949.
26. Pavelsky PM, Liu KD, Brophy PD, et al. KDQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61:649–672.
27. Okusa MD, Davenport A. Reading between the (guide) lines—the KDIGO practice guideline on acute kidney injury in the individual patient. Kidney Int. 2014;85:39–48.
28. Fox CS, Muntner P, Chen AY, et al. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012;125:497–504.
29. James MT, Ghali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78:803–809.
30. James MT, Ghali WA, Knudston ML, et al. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation. 2011;123:409–416.
31. Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. Circ Cardiovasc Interv. 2011;4:456–462.
32. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399.
33. Naria A, Mehran R, Weisz G, et al. Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. Eur Heart J. 2014;35:1533–1540.
34. Hata N, Yokoyama S, Shinada T, et al. Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. *Eur J Heart Fail.* 2010;12:32–37.
35. McCullough PA. Contrast-induced acute kidney injury. *J Am Coll Cardiol.* 2008;51:1419–1428.
36. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL evaluation along with B-type natriuretic peptide in acutely decompensated heart failure (GAL-LANT) trial. *Eur J Heart Fail.* 2011;13:846–851.
37. Jarai R, Dangas G, Huber K, et al. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. *Circ Cardiovasc Interv.* 2012;5:813–820.
38. Yang J, Goetz D, Li JY, et al. An iron delivery pathway mediated by a lipocalin. *Mol Cell.* 2002;10:1045–1056.
39. Koyner JL, Garg AX, Coca SG, et al. Biomarkers predict progression of acute kidney injury after cardiac surgery. *J Am Soc Nephrol.* 2012;23:905–914.
40. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. *Circ Cardiovasc Interv.* 2012;5:813–820.
41. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin. *J Am Soc Nephrol.* 2007;18:407–413.
42. Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. *Cancer Epidemiol.* 2012;36:e294–e299.
43. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin–siderophore–iron complex rescues the kidney from ischemia-reperfusion injury. *J Clin Invest.* 2005;115:610–621.
44. Striz I, Trebichavsky I. Calprotectin—an pleiotropic molecule in acute and chronic inflammation. *Physiol Res.* 2004;53:245–253.
45. Ehrench JM, Sanderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. *J Leukoc Biol.* 2009;86:557–566.
46. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nat Med.* 2007;13:1042–1049.
47. Katashima T, Naruko T, Terasaki F, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. *Circ. J.* 2010;74:741–748.
48. Ma LP, Haugen E, Ikemoto M, et al. S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. *Int J Cardiol.* 2012;155:26–32.
49. Shigeoka AA, Holscher TD, King AJ, et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. *J Immunol.* 2007;178:6252–6258.
50. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. *J Clin Invest.* 2005;115:2894–2903.
51. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. *J Clin Invest.* 2007;117:2847–2859.
52. Faubel S, Edelstein CL. Caspases as drug targets in ischemic organ injury. *Curr Drug Targets* *Immune Endocr Metabol Disord.* 2005;5:269–287.
53. Shi Y, Melnikov VY, Schrier RW, et al. Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemia-reperfusion. *Am J Physiol Renal Physiol.* 2000;279:F509–F517.
54. Melnikov VY, Ecker T, Fantuzzi G, et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. *J Clin Invest.* 2001;107:1145–1152.
55. Han WK, Wagener G, Zhu Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. *Clin J Am Soc Nephrol.* 2009;4:873–882.
56. McIlroy DR, Wagener G, Lee HT. Biomarkers of acute kidney injury: an evolving domain. *Anesthesiology.* 2010;112:998–1004.
57. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. *Kidney Int.* 2010;78:486–494.
58. Zhou H, Yuen PS, Pisitkun T, et al. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. *Kidney Int.* 2006;69:1471–1476.